Evidence map›Paper›PMID 38968193›Full record

ArticlePloS one2024

Clinical risk factors and blood protein biomarkers of 10-year pneumonia risk.

Ming-Ming Lee, Yi Zuo, Katrina Steiling, Joseph P Mizgerd, Bindu Kalesan, Allan J Walkey

Abstract read
In one paragraph

Article in PloS one, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 5 papers.

0numbers the graph read from it
0cells of the map it votes in
5citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

5 citing papers in PubMed.

  1. Harnessing breath biomarkers for pneumonia diagnosis and prognosis.Expert review of respiratory medicine · 2026
    Review
  2. Article
  3. Observational
  4. Article
  5. Article
4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

6 authors.

Ming-Ming LeePulmonary and Critical Care Medicine, Norwalk Hospital, Nuvance Health, Norwalk, CT, United States of America.
Yi ZuoDepartment of Biostatistics, Vanderbilt University, Nashville, TN, United States of America.
Katrina SteilingThe Pulmonary Center, Department of Medicine, Boston University School of Medicine, Boston, MA, United States of America.
Joseph P MizgerdThe Pulmonary Center, Department of Medicine, Boston University School of Medicine, Boston, MA, United States of America.
Bindu KalesanBoston University School of Medicine, Boston, MA, United States of America.
Allan J WalkeyDivision of Health Systems Science, Department of Medicine, UMass Chan Medical School, Worcester, MA, United States of America.ORCID 0000-0003-4685-6894

Funding

Pneumonia BiologyR35HL135756 · NHLBI · BOSTON UNIVERSITY MEDICAL CAMPUS · PI MIZGERD, JOSEPH P · 2017 to 2023
$6.6M
Lung-resident antibacterial heterotypic immunityR01AI115053 · NIAID · BOSTON UNIVERSITY MEDICAL CAMPUS · PI MIZGERD, JOSEPH P · 2015 to 2023
$4.0M
Pulmonary pathophysiology sub-phenotypes of pneumoniaR01AI162850 · NIAID · BOSTON UNIVERSITY MEDICAL CAMPUS · PI JOSEPH P MIZGERD · 2022 to 2026
$4.0M
Fibrin in the Infected LungR01HL171499 · NHLBI · BOSTON UNIVERSITY MEDICAL CAMPUS · PI JOSEPH P MIZGERD · 2024 to 2026
$2.3M
THE FRAMINGHAM HEART STUDY-N01HC25195-268025195-268025195N01HC025195 · HC · TRUSTEES OF BOSTON UNIVERSITY · PI WOLF, PHILIP A · 2002 to 2006
–
NHLBI NIH HHS HHSN268201500001CNHLBI NIH HHS HHSN268201500001INHLBI NIH HHS N01 HC025195NHLBI NIH HHS R01 HL171499NHLBI NIH HHS R35 HL135756NIAID NIH HHS R01 AI115053NIAID NIH HHS R01 AI162850
6 · The paper itself

Abstract

backgroundChronic inflammation may increase susceptibility to pneumonia. RESEARCH QUESTION: To explore associations between clinical comorbidities, serum protein immunoassays, and long-term pneumonia risk.

methodsFramingham Heart Study Offspring Cohort participants ≥65 years were linked to their Centers for Medicare Services claims data. Clinical data and 88 serum protein immunoassays were evaluated for associations with 10-year incident pneumonia risk using Fine-Gray models for competing risks of death and least absolute shrinkage and selection operators for covariate selection.

resultsWe identified 1,370 participants with immunoassays and linkage to Medicare data. During 10 years of follow up, 428 (31%) participants had a pneumonia diagnosis. Chronic pulmonary disease [subdistribution hazard ratio (SHR) 1.87; 95% confidence interval (CI), 1.33-2.61], current smoking (SHR 1.79, CI 1.31-2.45), heart failure (SHR 1.74, CI 1.10-2.74), atrial fibrillation/flutter (SHR 1.43, CI 1.06-1.93), diabetes (SHR 1.36, CI 1.05-1.75), hospitalization within one year (SHR 1.34, CI 1.09-1.65), and age (SHR 1.06 per year, CI 1.04-1.08) were associated with pneumonia. Three baseline serum protein measurements were associated with pneumonia risk independent of measured clinical factors: growth differentiation factor 15 (SHR 1.32; CI 1.02-1.69), C-reactive protein (SHR 1.16, CI 1.06-1.27) and matrix metallopeptidase 8 (SHR 1.14, CI 1.01-1.30). Addition of C-reactive protein to the clinical model improved prediction (Akaike information criterion 4950 from 4960; C-statistic of 0.64 from 0.62).

conclusionsClinical comorbidities and serum immunoassays were predictive of pneumonia risk. C-reactive protein, a routinely-available measure of inflammation, modestly improved pneumonia risk prediction over clinical factors. Our findings support the hypothesis that prior inflammation may increase the risk of pneumonia.

Indexed as

BiomarkersPneumoniaAgedAged, 80 and overBlood ProteinsCohort StudiesComorbidityFemaleHumansMaleRisk FactorsUnited StatesBiomarkersBlood Proteins

Identifiers

PMID38968193
PMCPMC11226120

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.